Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSUB64)

Drug Name

BAY 57-1293 Drug Info

Synonyms

Pritelivir; 348086-71-5; BAY-57-1293; UNII-07HQ1TJ4JE; AIC316; BAY57-1293; 07HQ1TJ4JE; Pritelivir (BAY 57-1293); N-Methyl-N-(4-methyl-5-sulfamoylthiazol-2-yl)-2-(4-(pyridin-2-yl)phenyl)acetamide; N-methyl-N-(4-methyl-5-sulfamoyl-1,3-thiazol-2-yl)-2-(4-pyridin-2-ylphenyl)acetamide; Pritelivir [INN]; AIC-316; AIC 316; AC1LANY1; PritelivirBAY-57-1293; SCHEMBL1074614; Pritelivir(BAY 57-1293); DTXSID70188344; EX-A247; MolPort-029-887-140; IVZKZONQVYTCKC-UHFFFAOYSA-N; HMS3653B15; BCP08742

Indication

Disease Entry	ICD 11	Status	REF
Herpes simplex virus infection	1F00	Phase 2	[1]

Cross-matching ID

PubChem CID: 491941
CAS Number: CAS 348086-71-5
TTD Drug ID: DMSUB64

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Herpes simplex virus Helicase-primase (HSV UL8)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
ASP-2151	DM5N1OB	Herpes simplex virus infection	1F00	Phase 3	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Herpes simplex virus Helicase-primase (HSV UL8)	TTKCVJR	HEPA_HHV11	Inhibitor	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01658826) Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes. U.S. National Institutes of Health.
2	Helicase primase: targeting the Achilles heel of herpes simplex viruses. Antivir Chem Chemother. 2004 May;15(3):135-40.
3	Efficacy of ASP2151, a helicase-primase inhibitor, against thymidine kinase-deficient herpes simplex virus type 2 infection in vitro and in vivo. Antiviral Res. 2012 Feb;93(2):301-4.